GLS and glioblastoma: Recent research using several GBM cell lines has found how the clinically relevant GLS inhibitor CB-839 suppressed GLS enzymatic activity, limiting the influx of Gln derivatives into the tricarboxylic acid cycle (TCAC) [21].